Biopar Delta-forte
NDC Package 64661-793-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Biopar Delta-forte is    BioparTMdelta-FORTE is indicated in the treatment of pernicious anemia and the prevention of folate deficiency;   BioparTM delta-FORTE is specifically indicated as a primary and adjunctive treatment in pernicious anemia patients having idiosyncrasy or sensitivity to parenteral administration - or when parental therapy is refused;   BioparTM delta-FORTE is further indicated in the maintenance of normal hematologic status (hematopoiesis) in macrocytic anemia conditions which are caused by either cobalamin and/or folate deficiency, and where increased intrinsic factor is desired - including:      1. Marketed by Jaymac Pharma, this product is identified by NDC 64661-793.

Identification & Billing

NDC Package Code
64661-793-30
Package Description
30 BLISTER PACK in 1 CARTON / 1 CAPSULE in 1 BLISTER PACK
Product Code
64661-793
11-Digit Billing Format
64661079330
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA

Clinical Specifications

Proprietary Name
Biopar Delta-forte
Dosage Form
-
Usage Information
   BioparTMdelta-FORTE is indicated in the treatment of pernicious anemia and the prevention of folate deficiency;   BioparTM delta-FORTE is specifically indicated as a primary and adjunctive treatment in pernicious anemia patients having idiosyncrasy or sensitivity to parenteral administration - or when parental therapy is refused;   BioparTM delta-FORTE is further indicated in the maintenance of normal hematologic status (hematopoiesis) in macrocytic anemia conditions which are caused by either cobalamin and/or folate deficiency, and where increased intrinsic factor is desired - including:      1. Malabsorption of cobalamin resulting from structural or functional damage to the stomach - where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates cobalamin absorption. Folate deficiency in these patients is usually more severe than cobalamin deficiency;      2. Genetic polymorphisms such as MTHFR that impede folate metabolism and the effective use of synthetic folic acid (oxidized form); and      3. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces cobalamin deficiency. Structural lesions leading to cobalamin deficiency include regional ileitis, ileal resections, malignancies, etc

Regulatory & Marketing

Labeler Name
Jaymac Pharma
Marketing Category
UNAPPROVED DRUG OTHER - An unapproved drug product in a marketing category that is not reflected on a particular list.
Start Marketing Date
06-01-2024
End Marketing Date
12-08-2025
Listing Expiration
12-08-2025
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 64661-793-30 identifies a specific commercial package of 30 blister pack in 1 carton / 1 capsule in 1 blister pack of Biopar Delta-forte, labeled by Jaymac Pharma. This product is billed for "EA" each discreet unit and contains an estimated amount of 30 billable units per package. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Jaymac Pharma on June 01, 2024. The current certification is valid through December 08, 2025.

How is this Jaymac Pharma product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 64661079330. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
64661-793-30
11-Digit CMS (5-4-2)
64661-0793-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.